Blinatumomab-driven T-cell activation in αβ and γδ T-cell subsets: insights from in vitro assays
Together, these <i>in vitro</i> data reveal subset-specific BLN responses and support the hypothesis that ex vivo-expanded Vγ9Vδ2 γδ T cells could complement BLN-mediated cytotoxicity, particularly under conditions of higher CD19 density and lower target burden. These findings provide a mechanistic framework for future testing of γδ T-cell/BLN combination strategies in patient-derived models and clinical studies.
Authors
- Ottmar Janßen (ORCID: https://orcid.org/0000-0002-9612-8900)
- Marta Lustig (ORCID: https://orcid.org/0009-0002-9368-5661)
- Miriam Kelm
- Anna Laqua
- Heiko Trautmann (ORCID: https://orcid.org/0000-0002-9000-4747)
- Sonja Bendig (ORCID: https://orcid.org/0009-0003-0644-9140)
- Daniela Wesch (ORCID: https://orcid.org/0000-0001-6509-208X)
- Christian Peters (ORCID: https://orcid.org/0000-0002-7669-3806)
- Thomas Valerius (ORCID: https://orcid.org/0000-0001-9181-8067)
- Dieter Kabelitz
- Hans-Heinrich Oberg
- Guranda Chitadze
- Monika Brüggemann
- Alexander Scheffold
- Claudia Dorothea Baldus
- Nourhan Nasr
Institutions
- Christian-Albrechts-Universität zu Kiel (DE)
- University Hospital Schleswig-Holstein (DE)
- Technische Universität Berlin (DE)
- Deutsche Forschungsgemeinschaft (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-06
- DOI
- https://doi.org/10.3389/fimmu.2026.1739493
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00